Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The IPI-GLIO trial has opened to recruitment.

This is an unblinded, open labelled stratified randomised Phase II multicentre clinical trial of ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma.

Patients with newly diagnosed de-novo glioblastoma following surgery and radical radiotherapy with concomitant temozolomide will be recruited from 7 sites in the UK, and randomly allocated to receive either ipilimumab and temozolomide or temozolomide alone. The first recruiting site to open is Mount Vernon Cancer Centre in Northwood.

IPI-GLIO is sponsored by the University of Oxford and managed by the Oncology Clinical Trials Office (OCTO). The trial is funded by Bristol-Myers Squibb and The National Brain Appeal. Statistical support is provided by the Centre for Statistics in Medicine (CSM). The Chief Investigator is Dr Paul Mulholland.

Similar stories

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.